Dr. Kerry Rogers on an Upcoming Phase I Clinical Trial of CDK9 Inhibitor VIP152 for Chronic Lymphocytic Leukemia (CLL)
This content was current as of the date it was released. In science and medicine, information is constantly changing and may become out-of-date as new data emerge.
The CLL Society partners with the nonprofit Coalition for Clinical Trials Awareness to increase trial awareness and participation for CLL and other cancer patients.
To learn more about the Coalition’s work, visit their website: http://cctawareness.org.
During Clinical Trials Awareness week, there will be several interesting blog posts worth reading on their site, but we wanted to highlight for our readers their upcoming web event on this Wednesday, May 20th at noon ET: COVID-19 and Clinical Trials: Treatments, Vaccines and Cures.
Click here to register.
We are very pro clinical trials and eager to see the trial opportunities expand for CLL patients.
I am a big believer in the benefits of clinical trials. It is the only way we move the science forward.
I am alive today because I enrolled in two early phase clinical trials, one for PCI-32765 that later became ibrutinib, and the other for JCAR-014, the CAR-T therapy that has my CLL in a full retreat.
Please visit our friends at Coalition for Clinical Trials Awareness and look at the offerings and their COVID-19 clinical trial event.
Stay strong, we are all in this together
Brian
Brian Koffman MDCM (retired) MS Ed
Co-Founder, Executive VP and Chief Medical Officer
CLL Society, Inc.
Related posts
